SmartZyme BioPharma

About:

SmartZyme is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes.

Website: http://smzyme.com

Twitter/X: SmartZyme

Top Investors: OrbiMed, Virtus Inspire Ventures

Description:

Better Continuous Glucose Monitors with a Next-Generation Glucose Sensing Enzyme SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.

Total Funding Amount:

$8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2013-01-01

Founders:

David Baram, Shilo Ben Zeev

Number of Employees:

11-50

Last Funding Date:

2018-03-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai